Aeterna Zentaris Receives Agreement from FDA on Special Protocol Assessment for Solorel

Aeterna Zentaris Inc.

today announced that it has reached agreement with the Food and Drug Administration on a Special Protocol Assessment for Solorel which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency.